Have I missed anything?
Let me know!
Low Dose Naltrexone Clinical Trials
A Randomized
Placebo-Controlled, Crossover-Design Study of the
Effects of Low Dose Naltrexone. (for
MS) Show
your Dr this study!
University of California, San Francisco February 2007
Jan 2008:
National MS Society clinical Update on LDN
Links to the research mentioned are available below.
Jan 2008:
Low Dose
Naltrexone for the Treatment of Fibromyalgia
Stanford Medical Center. Recruiting patients that live nearby.
Pilot multi-center study of low dose naltrexone in primary progressive
multiple sclerosis University of Milan.
Results to be presented at the American Academy of Neurology April 2008.
The Mali HIV+ AIDS LDN Initiative
-
Dr. Jaquelyn McCandless
Scottish
doctor is raising money to fund LDN drug trial for MS
Penn
State
Successful Trial of Low Dose Naltrexone for Crohn's
Disease
Evers
Multiple Sclerosis Clinic
The first trial of LDN
for Multiple Sclerosis was launched 10/2004 in Germany.
Pain
Therapeutics & Sourasky Medical Center
76% effectiveness of Low Dose Naltrexone for Irritable Bowel Syndrome
Met-enkephalin therapy for autoimmune diseases: Selective
immunomodulation and extention of steroid therapy
This human study was done in Croatia, 1997, and found
positive effects across multiple autoimmune conditions,
such as "significant reduction in the number and severity of relapses".
Met-enkephalin is the
endorphin released by LDN.
Research Papers related to Low Dose Naltrexone
New! The
Use of LDN for MS, Crohn's, and Other Autoimmune Diseases
by Elaine Moore,
who has published extensively on autoimmunity.
The role of glutamate transporters in neurodegenerative diseases and
potential opportunities for intervention.
Neurochem Int. 2007 Apr 19,
Sheldon AL, Robinson MB.
Possible importance of antibiotics and naltrexone in
neurodegenerative disease
(email for copy of article)
European Journal of Neurology 2005, 12: 1, Y.P. Agrawal
(If
you are interested in antibiotic treatment for MS click here.)
Low
dose naltrexone therapy in multiple sclerosis
Medical Hypotheses, 2005;64(4):721-4, Y.P.
Agrawal
Abstract
Full-PDF
Jan 2005: Interview
with LDN researcher Dr. Agrawal (PDF)
Interviewed by Robert
Lester, published by the Boston Cure Project
Dr
Zagon at
Penn State has a long research history with "opiod growth factor"
(invoked via LDN), and human trials for
Crohn's
Disease and Pancreatic
Cancer. The National MS Society has funded an animal study he
is doing to investigate LDN effects for MS.
Beta endorphin concentrations in PBMC of patients with different clinical
phenotypes of multiple sclerosis.
Dr
Gironi's research found lowered endorphins in MS patients. LDN
raises
endorphins, our own endogenous opiates, which may
have a modulating
effect on the immune system (see below).
Predictors
of Interferon Non-Response
If you are trying to
decide whether to continue Interferons or switch to LDN
Neuroimmunology References:
Discussion on the developing science of
neuroimmunology.
Related Research:
A team including JS Hong at the National Institutes of
Heath has been researching the neuroprotective effects other compounds
similar to Naltrexone:
Role
of Microglia in Inflammation-Mediated Neurodegenerative Diseases:
Mechanisms and Strategies for Therapeutic Intervention
Role
of nitric oxide in inflammation-mediated neurodegeneration
Inhibition by naloxone stereoisomers of beta-amyloid peptide
(1-42)-induced superoxide production in microglia and degeneration of
cortical and mesencephalic neurons
Dextromethorphan Protects Dopaminergic Neurons against
Inflammation-Mediated Degeneration through Inhibition of Microglial
Activation
